In this new article publication from Acta Pharmaceutica Sinica B, authors Beifen Zhong, Jun Wan and colleagues from the Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China discuss biosynthesis of rumbrins and inspiration for discovery of HIV inhibitors.
Investigation on how nature produces natural compounds with chemical and biological diversity at the genetic level offers inspiration for the discovery of new natural products and even their biological targets.
The polyketide rumbrin is a lipid peroxide production and calcium accumulation inhibitor, which contains a chlorinated pyrrole moiety that is a rare chemical feature in fungal natural products.
The authors of this article identify the biosynthetic gene cluster (BGC) rum of rumbrin and its isomer 12E-rumbrin from Auxarthron umbrinum DSM3193, and elucidate their biosynthetic pathway based on heterologous expression, chemical complementation, and isotopic labeling. It is demonstrated that rumbrins are assembled by a highly reducing polyketide synthase (HRPKS) that uniquely incorporate a proline-derived pyrrolyl-CoA starer unit and followed by methylation and chlorination. Sequent precursor-directed biosynthesis was able to yield a group of rumbrin analogues.
Inspired by the presence of a human immunodeficiency virus (HIV)-Nef-associated gene in the rum cluster, the authors predicted and pharmacologically demonstrated rumbrins as potent inhibitors of HIV at the nanomolar level. This work enriches the recognition of unconventional starter units of fungal PKSs and provides a new strategy for genome mining-guided drug discovery.
Article reference: Beifen Zhong, Jun Wan, Changhui Shang, Jiajia Wen, Yujia Wang, Jian Bai, Shan Cen, Youcai Hu, Biosynthesis of rumbrins and inspiration for discovery of HIV inhibitors, Acta Pharmaceutica Sinica B, 2022, ISSN 2211-3835, https://doi.org/10.1016/j.apsb.2022.02.005 .
Keywords: Rumbrins, Polyketide, Precursor-directed biosynthesis, Resistance gene, Anti-HIV activity
# # # # # #
The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.
For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/
APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).
Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).
Impact Factor: 11.614
JIF without self-citation: 10.746
# # # # #